Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Mass Balance of Lumicitabine in Healthy Males
NCT02231671Phase 1Completed
- Sponsor
- Alios BioPharma
- Start
- Aug 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lumicitabine in respiratory syncytial virus infection (RSV) (2 arms), sponsored by Alios BioPharma. Primary endpoints: Absolute Bioavailability and Mass Balance. Started Aug 2014; status: completed.
02
Drugs
lumicitabine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02231671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02231671.